The most frequent clinical entity of CTCL is mycosis fungoides (MF), accounting for about 60% of all cases, followed by primary cutaneous CD30+ lymphoproliferative disorders and much rarer entities such as Sézary syndrome (SS). This evidence concerns the gene TNFRSF8 and mycosis fungoides.